Delivery Order SPE2DB25D3404-SPE2DB25FUPVB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of TEZSPIRE 210 mg/1.91 ml auto-injector pens valued at $4,687.18. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contract requires completion by September 3, 2025, with performance taking place at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors, with an ultimate completion date of August 25, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued on August 4, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a biologic medication used for the treatment of severe asthma,...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pens on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract utilizes no set-aside designation and represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The work will be performed at...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- The Defense Logistics Agency (DLA) awarded a $14,061.54 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pens on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract utilizes no set-aside designation and represents a competitively awarded delivery order under the company's existing indefinite delivery contract with DLA. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injections on August 5, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction...
- The Defense Logistics Agency (DLA) awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of August 11, 2025. This non-set-aside contract was competitively awarded on July 21, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE is a specialty biologic medication used in the treatment of moderate-to-severe asthma, reflecting DLA's ongoing...
- The Defense Logistics Agency awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injections, with an ultimate completion date of August 8, 2025. This non-set-aside contract, awarded on July 18, 2025, represents a single delivery order fulfillment executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors. This competitive award, issued on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price transaction under a non-set-aside procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUPVBDelivery Order
The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pens on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract does not utilize a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE (tezepelumab) is a biologic treatment for moderate-to-severe asthma, representing a specialized pharmaceutical product within AmerisourceBergen's extensive portfolio of medical commodities supplied to federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime vendor agreement enables the company to supply a comprehensive range of pharmaceutical products and medical supplies supporting military healthcare programs globally. AmerisourceBergen's established relationship with DLA and demonstrated capability to fulfill diverse federal medical procurement requirements across multiple therapeutic domains positions the company as a critical vendor for the Defense Logistics Agency's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 8/14/25 |